Table of Contents

company-logo

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

PharmaCyte Biotech Dividend Announcement

• PharmaCyte Biotech does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on PharmaCyte Biotech dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

PharmaCyte Biotech Dividend History

PharmaCyte Biotech Dividend Yield

PharmaCyte Biotech current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing PharmaCyte Biotech stock? Use our calculator to estimate your expected dividend yield:

PharmaCyte Biotech Financial Ratios

P/E ratio0.51
PEG ratio0.26
P/B ratio0.26
ROE54.01%
Payout ratio83365097.94%
Current ratio4.40
Quick ratio4.40
Cash Ratio4.37

PharmaCyte Biotech Dividend FAQ

Does PharmaCyte Biotech stock pay dividends?
PharmaCyte Biotech does not currently pay dividends to its shareholders.
Has PharmaCyte Biotech ever paid a dividend?
No, PharmaCyte Biotech has no a history of paying dividends to its shareholders. PharmaCyte Biotech is not known for its dividend payments.
Why doesn't PharmaCyte Biotech pay dividends?
There are several potential reasons why PharmaCyte Biotech would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will PharmaCyte Biotech ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While PharmaCyte Biotech has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is PharmaCyte Biotech a dividend aristocrat?
PharmaCyte Biotech is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is PharmaCyte Biotech a dividend king?
PharmaCyte Biotech is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is PharmaCyte Biotech a dividend stock?
No, PharmaCyte Biotech is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy PharmaCyte Biotech stocks?
To buy PharmaCyte Biotech you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy PharmaCyte Biotech stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.